BioSpace News Archive

Shares of Regeneron are down following reports of increased observations of known side effects from blockbuster drug Eylea were reported by providing doctors.

Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.

Vertex Pharmaceuticals announced it is starting its first Phase III trial of VX-659, a triple combination of the VX-659, tezacaftor and ivacaftor for cystic fibrosis.

In an already competitive diabetes market, Novo Nordisk may have gained a significant edge with the results of its Phase III trial of GLP-1 drug oral semaglutide.

New York-based Kallyope Inc. has secured an additional $66 million in Series B funding that it will use to continue its work harnessing the communicative pathways between the digestive tract and the brain to develop new therapies for various illnesses.

GW Pharmaceuticals announced that its pipeline compound GWP42006 failed to meet its primary endpoint in a Phase IIa proof of concept study for patients with focal seizures.

Novartis is eying a possible 2019 launch for RTH258 (brolucizumab), an ophthalmology drug for the treatment of neovascular age-related macular degeneration.

Achillion is handing out pink slips to 20 percent of its employees and initiating an operational restructuring plan.

Zynex (OTCQB: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announced today that it will host the Company’s 2017 fourth quarter and full year investor webcast on Wednesday, February 28, 2018 at 9:00 a.m. Mountain Time (11:00 a.m. Eastern Time.)

4Tech Inc., a leader in the field of transcatheter tricuspid valve repair, announces changes in its leadership team: Tom Fleming will join the company as President and Chief Executive Officer (CEO), effective as of March 2018; and Keith D. Dawkins, M.D., has joined as Chief Medical Officer (CMO), effective immediately.